Company news
Acurx Pharmaceuticals, Inc. news in 2021
Acurx Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)
December 5, 2021
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update
November 11, 2021
Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference
November 7, 2021
Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek
October 3, 2021
Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference
September 26, 2021
Acurx Pharmaceuticals to Join the Russell Microcap Index®
September 1, 2021
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update
August 15, 2021
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021
August 11, 2021
Acurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving the Health of the Gut Microbiome
July 6, 2021
Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference
June 30, 2021
ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES
June 28, 2021
Acurx Pharmaceuticals, Inc. announces pricing of $15 Million underwritten Initial public offering of common stock
June 24, 2021
Calls in 2021
Decks in 2021
- IPO Roadshow (June 2021)
IPO roadshow · 22 slides · Jun 11, 2021